Discussing the lack of diversity in the psychedelics space with Jennifer Montjoy.
Similar Posts
Philadelic Conference Brings Together Interdisciplinary Experts to Advance Understanding of Psychedelics
The Philadelic Conference cultivates a setting of diverse experts to facilitate meaningful discussion, foster ideas, and expand understanding.
Interview with Ed Prideaux, Journalist at the Perception Restoration Foundation
In this episode, journalist Ed Prideaux discusses Hallucinogen Persisting Perception Disorder and some of the other very real risks involved with psychedelic misuse.
Is It Safe for Older People to Take Psychedelics? Here’s What the Research Says
As the global population ages, the question of whether psychedelics…
The Psychedelic CEO Round Table | feat. MindMed, Cybin, Field Trip and the Psychedelic Investor
The Psychedelic CEO Round Table | feat. MindMed, Cybin, Field Trip and the Psychedelic Investor
Join the Psychedelic Investor and the CEOs of MindMed (Rob Barrow) and Cybin (Doug Drysdale), and the Executive Chairman of Field Trip (Ronan Levy) as they discuss the future of psychedelic medicines.
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
If you are interested in investing in psychedelic stocks, then this is the even for you. Full of knowledge and unique information, this CEO discussion is a must.
Learn about the companies behind MindMed’s stock (Nasdaq: MNMD, NEO: MMED), Cybin’s stock (NYSE: CYBN, NEO: CYBN) and Field Trip Health’s stock (Nasdaq: FTRP, TSX: FTRP).
Presented by PsychedelicSpotlight.com, this conversation is as great a starting place as any to learn about psychedelic stocks
#Psychedelics #MindMed #Investing
Why I’m More Excited About MindMed’s 18-MC than its LSD treatments
Happy Holidays guys! I 🎄🙃 In this episode we’ll cover the many reasons why I’m more excited about MindMed’s 18-MC than its LSD treatments. As I mentioned in my previous video, the unfortunate fact is that the world is dealing with a second hidden epidemic: The Opioid Crisis. MindMed ( MMED/ MMEDF ) has a solution: 18-MC. Yes, MindMed has a diverse pipeline with other experiential drugs such as LSD for anxiety and psilocybin to treat ADHD. However, this psychedelic medicines company has its own proprietary compound (18-MC) to treat addiction which, if successful, cannot be copied by the upcoming competition. Keep watching to learn more about MindMed’s plan to end the opioid crisis with 18-MC. We may have a light at the end of the tunnel, and MindMed could potentially defeat the opioid epidemic threat, making MMED one of the best stocks for 2021.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
#mindmedstock
Kanna: “Nature’s MDMA” feat. Stephanie Wang
In this episode, Sacha sits down with Stephanie Wang, the founder of KA! Empathogenics. They get into the exciting benefits Kanna, sometimes dubbed as ‘Nature’s MDMA’.